Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Bone Marrow Transplantation|July 1, 2026
Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysisIvan J Huang, Grace T Baek, Qian Vicky Wu, et al.
Leukemia Research|January 28, 2014
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseasesPrashant R Tembhare, Constance M Yuan, David Venzon, et al.
Leukemia & Lymphoma|September 30, 2014
Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation methodElisabet E Manasanch, Dalia A Salem, Constance M Yuan, et al.
Leukemia & Lymphoma|January 15, 2013
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical studyBenjamin M Cherry, Neha Korde, Mary Kwok, et al.
Cytokine|July 22, 2014
Altered cytokine and chemokine profiles in multiple myeloma and its precursor diseaseAdriana Zingone, Weixin Wang, Meghan Corrigan-Cummins, et al.
Leukemia & Lymphoma|December 23, 2015
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imagingManisha Bhutani, Baris Turkbey, Esther Tan, et al.
Blood Advances|January 4, 2018
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myelomaSham Mailankody, Dickran Kazandjian, Neha Korde, et al.
Leukemia & Lymphoma|October 1, 2016
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasoneElisabet E Manasanch, Carlos Fernández de Larrea, Adriana Zingone, et al.
JAMA Oncology|September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled TrialDickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.
JAMA Oncology|July 17, 2015
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple MyelomaNeha Korde, Mark Roschewski, Adriana Zingone, et al.
Pageof 3